UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.37 Million Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 22.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 251,214 shares of the company’s stock after buying an additional 45,454 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.10% of Maravai LifeSciences worth $1,369,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Performa Ltd US LLC grew its stake in Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after buying an additional 4,300 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Maravai LifeSciences by 3,541.4% in the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock worth $56,000 after purchasing an additional 9,916 shares in the last quarter. Cibc World Markets Corp bought a new stake in shares of Maravai LifeSciences during the fourth quarter valued at approximately $56,000. Atria Investments Inc bought a new position in Maravai LifeSciences during the fourth quarter valued at approximately $58,000. Finally, Sherbrooke Park Advisers LLC purchased a new position in shares of Maravai LifeSciences in the fourth quarter worth approximately $78,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on MRVI shares. Stifel Nicolaus set a $5.00 target price on Maravai LifeSciences in a research report on Friday, March 21st. UBS Group decreased their target price on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a research report on Friday, March 21st. Robert W. Baird lowered their target price on Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, May 13th. Morgan Stanley reduced their price target on Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 25th. Finally, Baird R W lowered shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.64.

Maravai LifeSciences Stock Up 10.1%

Shares of MRVI stock opened at $2.39 on Monday. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.67 and a 1 year high of $10.03. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The business’s fifty day moving average is $2.05 and its 200-day moving average is $3.61. The stock has a market cap of $608.64 million, a PE ratio of -1.46 and a beta of 0.25.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million during the quarter, compared to analysts’ expectations of $44.01 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The business’s revenue was down 26.9% on a year-over-year basis. Equities analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.